Search

everythinglearnresearchcommunity

for

Search:↓

The user is discussing hair regrowth after 4.5 months of using oral dutasteride and minoxidil. Another user suggests improvement is possible and asks about exercise and diet.

A 19-year-old shares his hair loss experience and treatment routine, which includes 1mg finasteride daily, 2mg oral minoxidil daily, ketoconazole shampoo every 2 days, and a healthy lifestyle. He notes that oral minoxidil is showing better results than topical minoxidil.

The user experienced hair regrowth after 9 months using 0.5 mg dutasteride and 2.5 mg oral minoxidil, with initial shedding that reversed by the third month. The user reported no side effects and felt good overall.

The user has been using oral minoxidil at 10 mg daily, split between morning and night, alongside finasteride for 7 years, and reports new hair growth at the temples. Many users express concern over the high minoxidil dosage, citing potential health risks, while others question the effectiveness and necessity of such a dose.

The user had high DHT levels after 8 months on dutasteride, questioning the drug's authenticity. They got dutasteride from a legitimate source and will update on progress.

The user has been using oral Minoxidil and finasteride for a year, experiencing stronger and healthier hair with hope for further improvement. Many suggest a haircut to enhance appearance, while others encourage continuing the current regimen and possibly adding micro-needling.

Topical finasteride in Europe is often seen as less effective than oral forms, with users suggesting alternative application methods for better results. Many prefer oral finasteride due to cost and effectiveness.

Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.

Low-dose oral minoxidil is a safe and effective hair loss treatment with fewer side effects than previously feared. Users often prefer it over topical minoxidil for better results, though some experience side effects like increased body hair and cardiovascular issues.

The user experienced significant hair improvement after one year using topical finasteride and minoxidil, combined with a hair transplant at the front. They switched from oral to topical finasteride due to side effects and are satisfied with the results, especially at the temples.

A 27 year old's 3-month progress with topical finasteride and minoxidil solution, combined with weekly Nizoral shampoo. Replies to the post discuss the user's results, which are considered impressive, as well as the regimen used.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

Zeuss sublingual products for hair loss, including finasteride and a finasteride-free option, are discussed for their potential to reduce side effects through sublingual delivery. The inclusion of copper peptides is noted, but the high price is a concern without more user feedback.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

P5P supplementation helped reverse finasteride side effects, particularly by lowering prolactin levels and restoring sensitivity. The user experienced significant improvement within a day and full recovery in a few days.

The conversation discusses using B6 and Zinc to inhibit 5ar activity, similar to Fin and Dut. Minoxidil is mentioned as a supplementary treatment.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

The post discusses using a topical tincture containing zinc, azelaic acid, and other ingredients to inhibit 5 alpha-reductase activity for treating hair loss. The user plans to try this natural alternative before using finasteride or RU58841.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.